All In Biotech

Drug Trial Radar · NCT01868061

A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Last checked: Nov 19, 2026Latest source record: May 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,068 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,068

Actual

Start

Jul 31, 2013

Primary completion

Jan 2, 2017

Study completion Jan 2, 2017

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 4, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication. Participants will be randomized in 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered as subcutaneous (SC) injection every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. Participants who were assigned to placebo during the placebo-controlled period of the trial will be re-randomized at Week 52 to receive blinded SC lebrikizumab 37.5 milligrams (mg) or 125 mg every 4 weeks from Weeks 53 to 104. The anticipated time on study treatment is 104 weeks. After study treatment, all participants will complete a 20-week safety follow-up.

Conditions

  • Asthma

Interventions

  • LebrikizumabDrug

    Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

  • PlaceboDrug

    Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Asthma Exacerbations During the 52-Week Placebo-Controlled PeriodTime frame: Baseline up to Week 52

Locations

232 sites in 26 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama, LLC

    Birmingham, Alabama

  • Medical Research of Arizona; Allergy, Asthma & Immu

    Scottsdale, Arizona

  • Quality of Life Medical & Research Center

    Tucson, Arizona

  • Kern Allergy Med Clinic, Inc.

    Bakersfield, California

  • Allergy and Asthma Relief Experts

    Granada Hills, California

  • Southern California Institute For Respiratory

    Los Angeles, California

  • Allergy & Asthma Consultants

    Redwood City, California

  • Integrated Research Group Inc

    Upland, California

  • Allergy & Asthma Medical Group; Clinical Research Division

    Walnut Creek, California

  • Asthma & Allergy; Associates, P.C.

    Colorado Springs, Colorado

  • Storms Clinical Research; Institute

    Colorado Springs, Colorado

  • National Jewish Health

    Denver, Colorado

  • Colorado Allergy & Asthma Centers, Pc

    Denver, Colorado

  • Western States Clinical Research, Inc

    Wheat Ridge, Colorado

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Allergy Consultants PA

    Boca Raton, Florida

  • Research Institute of South Florida Inc

    Miami, Florida

  • Sarasota Clinical Research

    Sarasota, Florida

  • Georgia Pollens

    Albany, Georgia

  • Brookstone Clinical Res Ctr

    Columbus, Georgia

  • Southeast Regional Research Group

    Columbus, Georgia

  • DataQuest Medical Research

    Lawrenceville, Georgia

  • Aeroallergy Research Labs

    Savannah, Georgia

  • Atlanta Allergy & Asthma Clini

    Woodstock, Georgia

  • East-West Medical Research Institute

    Honolulu, Hawaii

  • Asthma & Allergy of Idaho

    Twin Falls, Idaho

  • The Allergy and Asthma Center

    Fort Wayne, Indiana

  • Cotton O'Neil Clinic; Stormont-Vail Hlth Care

    Topeka, Kansas

  • Dr. Paul Shapero

    Bangor, Maine

  • Asthma, Allergy & Sinus Center

    Baltimore, Maryland

  • Chesapeake Clinical Research

    Baltimore, Maryland

  • Howard County Center for Lung and Sleep, LLC

    Columbia, Maryland

  • Infinity Medical Research Inc

    North Dartmouth, Massachusetts

  • Clinical Research Inst

    Minneapolis, Minnesota

  • Asthma and Allergy Physicians LLC

    Brockton, Mississippi

  • Allergy Associates, Inc.

    Chesterfield, Missouri

  • Center For Pharmaceutical Research

    Kansas City, Missouri

  • Clinical Research Center, L.L.C.

    St Louis, Missouri

  • Clinical Research Consortium

    Las Vegas, Nevada

  • Adult Pediatric Allergy Central Jersey

    Edison, New Jersey

Showing 40 of 232 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.